Differential response of angiotensin peptides in the urine of hypertensive animals
- PMID: 10235635
- DOI: 10.1016/s0167-0115(99)00005-1
Differential response of angiotensin peptides in the urine of hypertensive animals
Abstract
Urinary excretion rates of angiotensin I (Ang I), angiotensin II (Ang II), and angiotensin-(1-7) [Ang-(1-7)] were determined in normotensive Sprague Dawley (SD), spontaneously hypertensive (SHR), and mRen-2 transgenic hypertensive animals before and following blockade of Ang II synthesis or activity for two weeks. This study was performed to determine for the first time whether inhibition of Ang II alters the excretion of angiotensin peptides in the urine. Rats were given either tap water or water medicated with lisinopril, losartan or both agents in combination. Blood pressure was monitored at regular intervals during the experiment by the tail-cuff method, and once again at the end of the study with a catheter implant into a carotid artery. Metabolic studies and 24 h urinary excretion variables and angiotensin peptides were determined before and during the procedures. While all three treatments normalized the blood pressure of hypertensive animals, therapy with either lisinopril or the combination of lisinopril and losartan had a greater antihypertensive effect in both SHR and [mRen-2]27 transgenic hypertensive rats. In the urine, the concentration of the angiotensins (normalized by 24-h creatinine excretion) was several-fold higher in the untreated hypertensive animals than in normotensive SD rats. In SD rats, lisinopril or lisinopril and losartan produced a sustained rise in urinary levels of Ang-(1-7) without changes in the excretion of Ang I and Ang II. In contrast, Ang I and Ang-(1-7) were significantly elevated in SHR medicated with lisinopril alone or in combination with losartan. Only losartan, however, augmented urinary levels of Ang II in the SHR. The antihypertensive effects of the three separate regimens had no effect on the urinary excretion of angiotensin peptides in [mRen-2]27 transgenic hypertensive rats. These data show that Ang I and Ang-(1-7) are excreted in large amounts in the urine of SD, SHR and [mRen-2]27 hypertensive rats. The unchanged Ang-(1-7) excretion in transgenic hypertensive (Tg+) rats after inhibition of the renin-angiotensin system agrees with the previous finding of a reduced plasma clearance of the peptide in this model of hypertension. The data suggest that this form of hypertension may be associated with increased activity of an endogenous converting enzyme inhibitor.
Similar articles
-
Converting enzyme determines plasma clearance of angiotensin-(1-7).Hypertension. 1998 Sep;32(3):496-502. doi: 10.1161/01.hyp.32.3.496. Hypertension. 1998. PMID: 9740616
-
Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2166-72. doi: 10.1152/ajpheart.00061.2006. Epub 2006 Jun 9. Am J Physiol Heart Circ Physiol. 2006. PMID: 16766648
-
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.Kidney Int. 2005 Nov;68(5):2189-96. doi: 10.1111/j.1523-1755.2005.00675.x. Kidney Int. 2005. PMID: 16221218
-
Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system.Regul Pept. 1998 Nov 30;78(1-3):13-8. doi: 10.1016/s0167-0115(98)00134-7. Regul Pept. 1998. PMID: 9879742 Review.
-
A developmental genetic mechanism involving angiotensin in spontaneously hypertensive rats.Clin Exp Pharmacol Physiol Suppl. 1992;19:19-22. doi: 10.1111/j.1440-1681.1992.tb02805.x. Clin Exp Pharmacol Physiol Suppl. 1992. PMID: 1395112 Review.
Cited by
-
Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney.Sci Rep. 2016 Sep 21;6:33678. doi: 10.1038/srep33678. Sci Rep. 2016. PMID: 27649628 Free PMC article.
-
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function.Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2281-90. doi: 10.1152/ajpheart.00618.2005. Epub 2005 Jul 29. Am J Physiol Heart Circ Physiol. 2005. PMID: 16055515 Free PMC article. Review.
-
Mas receptor: a potential strategy in the management of ischemic cardiovascular diseases.Cell Cycle. 2023 Jul;22(13):1654-1674. doi: 10.1080/15384101.2023.2228089. Epub 2023 Jun 26. Cell Cycle. 2023. PMID: 37365840 Free PMC article. Review.
-
Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats.Br J Pharmacol. 2002 Apr;135(7):1743-8. doi: 10.1038/sj.bjp.0704630. Br J Pharmacol. 2002. PMID: 11934815 Free PMC article.
-
Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).Adv Pharmacol. 2010;59:197-233. doi: 10.1016/S1054-3589(10)59007-0. Adv Pharmacol. 2010. PMID: 20933203 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous